Medical Alley, MN – The Medical Alley Association is pleased to welcome Bio-Techne as its newest sustaining member!
“We are extremely excited to further our relationship with the Medical Alley Association as a Sustaining Member. Bio-Techne’s focus on developing cutting edge life science tools to enable scientific and drug discoveries as well as clinical diagnostics to improve the diagnosis of specific diseases align with Medical Alley’s healthcare leadership and innovation priorities,” said Chuck Kummeth, President and Chief Executive Officer of Bio-Techne. “We look forward to continuing to shape the future of healthcare with the industry leaders in the Medical Alley Association.”
Bio-Techne is a leader in Medical Alley’s growing life sciences sector. This year, Bio-Techne completed an expansion into St. Paul, investing almost $50M in a state of the art manufacturing facility. Additionally, through a partnership with Kantaro Biosciences (a Mount Sinai Health System and diagnostics start-up RenalytixAI joint venture), Bio-Techne recently received FDA authorization for the commercialization of a COVID-19 test that determines the presence and precise level of IgG antibodies, an important step in further understanding immunity against the virus.
“Bio-Techne is already well-known as a leader in Medical Alley, and we are pleased to welcome them as a sustaining member. From the recent expansion in St. Paul, to a key role in developing a groundbreaking COVID-19 antibody test, I look forward to their leadership and expertise as we continue the important work to solidify Medical Alley as The Global Epicenter of Health Innovation and Care™,” said Shaye Mandle, President and CEO of the Medical Alley Association.
Bio-Techne joins a unique and impressive group of companies at the sustaining membership level from every sector of healthcare who are working to transform the future of healthcare.
